

Preliminary Study of Incidence of MDR *Burkholderia cepacia* in Nile Tilapia in Egypt

Mahmoud E. Elsayed¹, Reham M. El-Tarabili¹, Hanan Elghayaty², Zainab Mohamed Ali El Kattawy³

¹Department of Bacteriology, Immunology and Mycology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt.

rehameltrabely@gmail.com

²Animal Health Institute, Portsaid branch, Egypt

³Free Veterinarian

Abstract

It is not well known if *Burkholderia cepacia* can be found in fish or water. This is because bacteria may enter into the water through sewage, animal waste, and soil runoff. Therefore, the current study was carried out to assay the incidence of biochemically identified *Burkholderia cepacia* in seventy-five Nile Tilapia and twenty-five water samples collected from Elmanzala Lake, Egypt, with API 20 NE and its antibiotic resistance. Three *B.cepacia* isolates were identified from 100 samples with aprevalence 3%. Two from fish (only gills) with a prevalence 2.7%(2/75) and one from the water sample with a prevalence 4%(1/25). Only one isolate was MDR with 0.43 MAR index. Besides, all isolates were susceptible to levofloxacin, meropenem, and chloramphenicol, while, recovered isolates were resistant to ceftazidime (100%), penicillin G(66.6%), and trimethoprim/ sulfamethoxazole (33.4%). This study concluded that MDR *B.cepacia* is of importance in public health, and is considered human health issue. Meropenem ,cholramphenicol and levofloxacin used as drug of choice for treatment *B.cepacia*.

Keywords: *Burkholderia cepacian*, Nile Tilapia, MDR

1. Introduction

The most significant disease concerns in aquaculture are caused by bacterial infections, which are naturally present in fish environments. *Burkholderia* are non-spore-forming, Gram-negative aerobic bacteria. These organisms are adaptable to several biological environments, including soil, water, animals, and human respiratory

tracts (*Coenye and Vandamme, 2003*).

Burkholderia, a multi-species bacterial genus, has nine phenotypically similar species known as the *Burkholderia cepacia* complex (Bcc) (*Luvizotto and Marcon, 2010*). (*Yabuuchi et al. 1992*) named the genus *Burkholderia* after Burkholder, who discovered it but classified it as *Pseudomonas* (*Burkholder, 1950*).

B. cepacia complex (Bcc) as a food-spoilage organism. Bcc is a life-threatening infection, especially in individuals with cystic fibrosis (LiPuma, 1998a) and chronic granulomatous disease (Speert et al., 1994). Some cases of endocarditis and nosocomial infection outbreaks have been associated with *B. cepacia* (Hirose et al., 1998; Kaitwatcharachai et al., 2000). Although reports of Bcc-caused animal illnesses recorded (Berriatua et al., 2001), the distribution of Bcc in animal species and its transmission are generally not well reported.

The extensive usage of antimicrobial drugs has assisted in the emergence of multidrug-resistant organisms (Levy, 2002; Algammal et al., 2022a). Most antimicrobial drugs do not affect Bcc. Effective treatments are not always easy to understand. Thus, the primary objective of management efforts is the prevention of related infections (LiPuma, 1998b; Algammal et al., 2022b). Thus, the purpose of this investigation is to identify the prevalence of *B. cepacia* in fish and to evaluate its possible role as a source of infection especially from water with its antibiotic resistance.

2. Materials and methods

2.1. Sampling

Seventy-five diseased Nile tilapia (*Oreochromis niloticus*) showed signs of petechial haemorrhages and erosions on skin and twenty-

five water samples with normal parameters were obtained from Elmanzala Lake, Egypt from June to September 2023. Further clinical and bacteriological assessments of the collected fish were carried out in aerated sealed plastic bags in the laboratory.

2.2. Isolation of *Burkholderia cepacia*

Loopfuls from the fish (liver, kidney, gills), and water samples were examined to assess the presence of *Burkholderia cepacia*, which was isolated and identified (Henry et al., 1997). The samples were inoculated on trypticase soya agar (Oxoid, UK) with 5% sheep blood (Oxoid, UK) and MacConkey agar (Oxoid, UK), and the plates were incubated at 35 °C for 24 hours.

2.3. *Burkholderia cepacia* Identification

Microscopical examination of Gram-stained films and culture characterization. All cultures that produce a positive oxidase reaction were classified as prospective *Burkholderia cepacia* and were kept for further identification using the API 20 NE system (bioMérieux, SA, France). Catalase, nitrate reduction, gelatin hydrolysis, Lysine decarboxylase, and Ornithine decarboxylase, indole, glucose fermentation, arginine hydrolysis, and urease were performed on suspected colonies.

2.4. AntibioGram Testing

Antimicrobial sensitivity of *Burkholderia cepacia* isolates

(NCCLS standards (1997) by disk diffusion method against seven antimicrobial agents categorized into seven classes including penicillin G(PEN) (10 U), amoxicillin-clavulanic acid (AMC) (30 µg), meropenem (MEM) (10 µg), ceftazidime (CAZ) (30 µg), levofloxacin (LEV) (5 µg), sulfamethoxazole/trimethoprim (SXT) (25 µg), and chloramphenicol (C) (25 µg).

3. Results

3.1. Prevalence of *Burkholderia cepacia* among Examined Fish

Morphologically, all the retrieved *Burkholderia cepacia* isolates were Gram-negative, bacilli. The colonies on macCkongy agar plates were pale and non-lactose fermenter (Figure 1A) and gave beta hemolysis on blood agar (Figure 1B). Biochemically, all the recovered isolates were positive for oxidase, catalase, nitrate reduction, gelatin hydrolysis, Lysine decarboxylase, and Ornithine

decarboxylase. While all the recovered isolates were negative for indole, glucose fermentation, arginine hydrolysis, and urease (Table 1). In addition, the API20NE confirmed the identification of all obtained isolates with a probability of 100% (454557). The prevalence of *Burkholderia cepacia* among the examined samples was 3% (3/100). Two from fish (only gills) with a prevalence 2.7% (2/75) and one from the water sample with a prevalence 4% (1/25).

3.2. Antibiogram results

The result of the antibiogram of three strains isolated from Nile tilapia. Table (2) revealed that three isolates were resistant to ceftazidime (100%), penicillin G (66.6%), and trimethoprim/sulfamethoxazole (33.4%) and sensitive to levofloxacin, meropenem, and chloramphenicol (100%) and one isolate considered as MDR. MARI was determined as 0.14 to 0.43.




Figure 1 A: Pale and non-lactose colonies on macCkongy agar. **B:** Beta hemolysis colonies on blood agar.

Table 1 : Biochemical identification of *B.cepacia*

Biochemical test	<i>B.cepacia</i>
Oxidase	Positive
Catalase	Positive
Nitrate reduction	Positive
Urease	Negative
Indole	Negative
Glucose fermentation	Negative
Gelatin hydrolysis	Positive
Lysine decarboxylase	Positive
Ornithine decarboxylase	Positive
arginine hydrolysis	Negative

Table 2:Antibiogram results of recovered isolates

Antibiotic classes	Antibiotic agent	Sensitive	Resistant
Penicillins	Penicillin G	1(33.4%)	2(66.6%)
	Amoxicillin/Clavulanic acid	3(100%)	0(0)
Cephalosporin	Ceftazidime	0(0)	3(100%)
Carpebenem	Meropenem	3(100%)	0(0)
Fluoroquinolone	Levofloxacin	3(100%)	0(0)
Phenicols	Chloramphenicol	3(100%)	0(0)
Sulfonamides	Trimethoprim/ sulfamethoxazole	2(66.6%)	1(33.4%)

Discussion

Burkholderia cepacia in water and fish indicated high contamination. In addition, this study aimed to detect *Burkholderia cepacia* in fish and its antibiotic sensitivity. Our study revealed an incidence of *B.cepacia* 2.7%(2/75) in Nile Tilapia and 4% in the water samples with its total prevalence (3%) similar to (El-Barbary and Hal ,2017). who identified three *B.cepacia* isolates in fish. Bcc in food is a major problem because of its capacity to proliferate at low temperatures and its emergence as

an opportunistic pathogen, particularly for cystic fibrosis patients, which can cause life-threatening infections (Nagah et al., 2012).

Several studies have shown problems with phenotypic approaches misidentifying *Burkholderia* species (Kiska et al., 1996, Henry et al., 1997 Henry et al., 2001). Phenotypic classification approaches may not be sufficient for identifying *Burkholderia cepacia*, although the API 20NE successfully identified all three strains recovered from fish.

(Wiedmann *et al.*, 2000) found that API 20NE accurately identified *Pseudomonas* isolates and (El-Barbary and Hal, 2017) identified *Burkholderia cepacia*.

These findings support the occurrence of MDR *B.cepacia* isolates in aquaculture sectors and demonstrate that the food chain might spread MDR pathogens between animals and humans (Algammal *et al.*, 2022a). Randomly treating developing infections with antibiotics may cause MDR strains in aquaculture. Thus, routine antibiotic susceptibility testing is essential for selecting effective antibiotics and resolving such issues (Algammal *et al.*, 2022b). Upon examining *B.cepacia* antibiotic sensitivity in Table 2, isolates showed resistance to multiple antibiotics. All isolates proved resistant to ceftazidime (100%), while 33.4% were susceptible to penicillin and 66.6% sensitive to Trimethoprim/sulfamethoxazole. (Isles *et al.*, 1984) discovered that Bcc isolates were resistant to ampicillin (97%), gentamicin (97%), and chloramphenicol (45%). Additional studies on Bcc species revealed extensive resistance (Nzula *et al.*, 2002; Zhou *et al.*, 2007).

Conclusion

This study found MDR *Burkholderia cepacia* in Nile Tilapia and water which can cause infection as first reported in Egypt. Meropenem

, chloramphenicol and levofloxacin used as drug of choice for treatment *B.cepacia*. *Burkholderia cepacia* is antibiotic-resistant, and people infected may not respond to treatment. *Burkholderia cepacia* eradication as a human pathogen will become more emergent.

References

- Algammal, A. M., Mabrok, M., Ezzat, M., Alfifi, K. J., Esawy, A. M., Elmasry, N., & El-Tarabili, R. M. (2022a). Prevalence, antimicrobial resistance (AMR) pattern, virulence determinant and AMR genes of emerging multi-drug resistant *Edwardsiella tarda* in Nile tilapia and African catfish. *Aquaculture*, 548, 737643.
- Algammal, A. M., Alfifi, K. J., Mabrok, M., Alatawy, M., Abdel-Moneam, D. A., Alghamdi, S., ... & El-Tarabili, R. M. (2022c). Newly Emerging MDR *B. cereus* in *Mugil seheli* as the First Report Commonly Harbor *hbl*, *cyt K*, and *pc-plc* Virulence Genes and *bla* 1, *bla* 2, *tet A*, and *erm A* Resistance Genes. *Infection and Drug Resistance*, 2167-2185.
- Algammal AM, Ibrahim RA, Alfifi KJ, Ghabban H, Alghamdi S, Kabrah A, Khafagy AR, Abou-Elela GM, Abu-Elala NM, Donadu MG, El-Tarabili RM (2022c). A First Report of Molecular Typing, Virulence Traits, and Phenotypic and Genotypic Resistance Patterns of Newly Emerging XDR and MDR *Aeromonas veronii* in *Mugil seheli*.

- Pathogens. 2022 Oct 29;11(11): 1262.
- Berriatua, E.; Ziluaga, I.; Miguel-Virto, C.; Uribarren, P.; Juste, R.; Laevens, S.; Vandamme, P. and Govan, J.R.W. (2001):** Outbreak of subclinical mastitis in a flock of dairy sheep associated with *Burkholderia cepacia* complex infection. J. Clin. Microbiol, 39 (3): 990–994.
- Burkholder, W. (1950):** Sour skin, a bacterial rot of onion bulbs. Phytopath., 40: 115-117.
- Coenye, T. and Vandamme, P. (2003):** Diversity and significance of *Burkholderia* species occupying diverse ecological niches. Enviro. Microbiol., 5 (9): 719-729.
- El-Barbary, M. I., & Hal, A. M. (2017):** Phenotypic and genotypic characterization of some *Pseudomonas* sp. associated with *Burkholderia cepacia* isolated from various infected fishes. Journal of Aquaculture Research and Development, 8 (7), 1-7.
- Henry, D. A., M. E. Campbell, J. J. LiPuma, and D. P. Speert. (1997):** Identification of *Burkholderia cepacia* isolates from patients with cystic fibrosis and use of a simple new selective medium. J. Clin. Microbiol. 35:614–619.
- Henry, D. A., Mahenthalingam, E., Vandamme, P., Coenye, T., & Speert, D. P. (2001):** Phenotypic methods for determining genomovar status of the *Burkholderia cepacia* complex. Journal of Clinical Microbiology, 39(3), 1073-1078.
- Hirose, S.; Nakano, K.; Kosakai, Y.; Sasaki, T.; Kobayashi, J.; Sasako, Y.; Yamamoto, E.; Ueda, H.; Yutani, C. and Kitamura, S. (1998):** Surgical treatment for prosthetic valve endocarditis. J. Cardiol., 31:85- 89
- Isles, A.; Maclusky, I.; Corey, M.; Gold, R.; Prober, C.; Fleming, P. and Levison, H. (1984):** *Pseudomonas cepacia* infection in cystic fibrosis: an emerging problem. J. Pediatr., 104 (2): 206–210.
- Kaitwatcharachai, C.; Silpapojakul, K.; Jitsurong, S. and Kalnauwakul, S. (2000):** An outbreak of *Burkholderia cepacia* bacteremia in hemodialysis patients: An epidemiologic and molecular study. Am. J. Kidney Dis., 36: 199-204
- Kiska, D. L., A. Kerr, M. C. Jones, J. A. Caracciolo, B. Eskridge, M. Jordan, S. Miller, D. Hughes, N. King, and P. Gilligan. (1996):** Accuracy of four commercial systems for identification of *Burkholderia cepacia* and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J. Clin. Microbiol. 34:886–891
- Levy, S.B. (2002):** Factors impacting on the problem of antibiotic resistance. J. Antimicrob. Chemother., 49: 25-30. LiPuma, J.J. (1998a): *Burkholderia cepacia* epidemiology and pathogenesis: implications for infection control. Curr. Opin. Pulm. Med., 4: 337- 441.

- LiPuma, J.J. (1998b):** *Burkholderia cepacia*: management issues and new insights. Clin. Chest Med., 19: 473- 486.
- Luvizotto, D. and Marcon, J. (2010):** Genetic diversity and plant-growth related features of *Burkholderia* spp. from sugarcane roots. World J. Microbiol. Biotechnol., 26: 1829-1836.
- Nagah M S and Amin, W. F.,(2012):** Isolation Of *Burkholderia Cepacia* Complex From Raw Milk Of Different Species Of Dairy Animals In Assiut Governorate. Assiut Veterinary Medical Journal, , 58.135: 67-70.
- NCCLS (National Committee for Clinical Laboratory Standards) (1997):** Approved standard M2-A6. Performance standards for antimicrobial disc susceptibility tests. 6th Ed. NCCLS, Wayne, PA.
- Nzula, S.; Vandamme, P. and Govan, J. (2002):** Influence of taxonomic status on the in vitro antimicrobial susceptibility of the *Burkholderia cepacia* complex. J. Antimicrob. Chemother., 50 (2): 265–269.
- Speert, D.P.; Bond, M.; Woodman, R.C. and Curnette, J.T. (1994):** Infection with *Pseudomonas cepacia* in chronic granulomatous disease: role of nonoxidative killing by neutrophils in host defence. J. Infect. Dis., 170: 1523- 1531.
- Yabuuchi, E.; Kosako, Y.; Oyaizu, H.; Yano, I.; Hotta, H.; Hashimoto, Y.; Ezaki, T. and Arakawa, M. (1992):** Proposal of *Burkholderia* gen. nov. and transfer of seven species of the genus *Pseudomonas* homology group II to the new genus, with the type species *Burkholderia cepacia* comb. nov. Microbiol Immunol., 36: 1251-1275.
- Wiedmann M, Weilmeier D, Dineen SS, Ralyea R, Boor KJ (2000):** Molecular and phenotypic characterization of *Pseudomonas* sp. isolated from milk. Appl Environ Microbiol 66: 2085-2095.
- Zhou, J.; Chen, Y.; Tabibi, S.; Alba, L.; Garber, E. and Saiman, L. (2007):** Antimicrobial susceptibility and synergy studies of *Burkholderia cepacia* complex isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother., 51 (3): 1085–1088.

الملخص العربي

دراسة أولية لحدوث عقار بيركهولديريا سيباسيا المقاوم للأدوية المتعددة في البلطي

النيلي في مصر

محمود عزت¹ - ريهام الطرابيلي¹ و حنان الغياتي² و زينب محمد القطاوي³

¹ قسم البكتيريا والمناعة والفطريات، كلية الطب البيطري، جامعة قناة السويس، الإسماعيلية

41522، مصر

² معهد صحة الحيوان فرع بورسعيد مصر

³ طبيب بيطري حر

لم يتم توثيق وجود بكتيريا *Burkholderia cepacia* بشكل جيد في الأسماك والمياه حيث يمكن للبكتيريا أن تدخل الماء من خلال التربة ومياه الصرف الصحي وفضلات الحيوانات. لذلك، تم إجراء الدراسة الحالية لتقدير حدوث *Burkholderia cepacia* في خمسة وسبعين عينة من أسماك البلطي النيلي وخمسة وعشرين عينة مياه تم جمعها من بحيرة المنزلة، مصر، عن طريق العزل والتعرف الكيميائي الحيوي باستخدام API 20 NE والمقاومة للمضادات الحيوية. تم تشخيص ثلاث عزلات من بكتيريا *B.cepacia* من 100 عينة. عزلتان من الأسماك (الخياشيم فقط) بنسبة انتشار 2.7% (75/2) وعزله من عينة المياه بنسبة انتشار 4% (25/1). عزلة واحدة فقط كانت MDR بمؤشر MAR 0.43. الى جانب ذلك، كانت جميع العزلات حساسة للنيوفلوكساسين، الميروبينييم، والكلورامفينيكول، في حين كانت العزلات المستردة مقاومة للسيفتازيديم (100%)، البنسلين ج (66.6%)، وتريميثوبريم / سلفاميثوكسازول (33.4%). وتم الاستنتاج في هذه الدراسة إلى أن MDR *B.cepacia* له أهمية للصحة العامة، ويعتبر قضية صحية تهدد لإنسان.